Morbilliform drug eruptions

Uzoamaka T. Ukoha, Amit G. Pandya, Arturo R. Dominguez

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Morbilliform drug eruptions, also called exanthematous drug eruptions, are a form of delayed cutaneous hypersensitivity characterized by erythematous macules or papules that coalesce to form large plaques. The eruption usually occurs 5 days to 2 weeks after administration of the causative agent. The most common causes are antibiotics, Anti-Epileptics, allopurinol, nonsteroidal anti-inflammatories (NSAIDS), anxiolytics, Anti-Hypertensives, and diuretics. They can also be associated with viral infections, illicit drug use, blood products, IV contrast media, and may have a genetic predisposition. With the cessation of the causative drug, morbilliform eruptions usually resolve within 1-2 weeks. The main histological features of morbilliform drug eruptions are a superficial and deep perivascular infiltrate and interstitial spongiotic and psoriasisiform dermatitis in conjunction with vacuolar interface changes. Although not completely understood, the immunological mechanisms for morbilliform drug eruptions involve a type IVb and IVc hypersensitivity reaction, as described by Gell and Coombs. Treatment for exanthematous drug reactions includes cessation of the causative agent and treatment of symptoms associated with the reaction, particularly pruritus.

Original languageEnglish (US)
Title of host publicationCutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy
PublisherSpringer-Verlag London Ltd
Pages45-53
Number of pages9
ISBN (Print)9781447167297, 9781447167280
DOIs
StatePublished - Aug 21 2015

Fingerprint

Drug Eruptions
Allopurinol
Anti-Anxiety Agents
Delayed Hypersensitivity
Street Drugs
Dermatitis
Virus Diseases
Pruritus
Genetic Predisposition to Disease
Diuretics
Contrast Media
Antihypertensive Agents
Hypersensitivity
Anti-Inflammatory Agents
Gels
Anti-Bacterial Agents
Skin
Pharmaceutical Preparations

Keywords

  • Adverse drug reactions
  • Cutaneous drug reactions
  • Drug eruptions
  • Exanthematous drug eruptions
  • Morbilliform drug eruptions

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Immunology and Microbiology(all)

Cite this

Ukoha, U. T., Pandya, A. G., & Dominguez, A. R. (2015). Morbilliform drug eruptions. In Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy (pp. 45-53). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-6729-7_5

Morbilliform drug eruptions. / Ukoha, Uzoamaka T.; Pandya, Amit G.; Dominguez, Arturo R.

Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd, 2015. p. 45-53.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ukoha, UT, Pandya, AG & Dominguez, AR 2015, Morbilliform drug eruptions. in Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd, pp. 45-53. https://doi.org/10.1007/978-1-4471-6729-7_5
Ukoha UT, Pandya AG, Dominguez AR. Morbilliform drug eruptions. In Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd. 2015. p. 45-53 https://doi.org/10.1007/978-1-4471-6729-7_5
Ukoha, Uzoamaka T. ; Pandya, Amit G. ; Dominguez, Arturo R. / Morbilliform drug eruptions. Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd, 2015. pp. 45-53
@inbook{2a40f0d0802a4f52aa7dc34924017de3,
title = "Morbilliform drug eruptions",
abstract = "Morbilliform drug eruptions, also called exanthematous drug eruptions, are a form of delayed cutaneous hypersensitivity characterized by erythematous macules or papules that coalesce to form large plaques. The eruption usually occurs 5 days to 2 weeks after administration of the causative agent. The most common causes are antibiotics, Anti-Epileptics, allopurinol, nonsteroidal anti-inflammatories (NSAIDS), anxiolytics, Anti-Hypertensives, and diuretics. They can also be associated with viral infections, illicit drug use, blood products, IV contrast media, and may have a genetic predisposition. With the cessation of the causative drug, morbilliform eruptions usually resolve within 1-2 weeks. The main histological features of morbilliform drug eruptions are a superficial and deep perivascular infiltrate and interstitial spongiotic and psoriasisiform dermatitis in conjunction with vacuolar interface changes. Although not completely understood, the immunological mechanisms for morbilliform drug eruptions involve a type IVb and IVc hypersensitivity reaction, as described by Gell and Coombs. Treatment for exanthematous drug reactions includes cessation of the causative agent and treatment of symptoms associated with the reaction, particularly pruritus.",
keywords = "Adverse drug reactions, Cutaneous drug reactions, Drug eruptions, Exanthematous drug eruptions, Morbilliform drug eruptions",
author = "Ukoha, {Uzoamaka T.} and Pandya, {Amit G.} and Dominguez, {Arturo R.}",
year = "2015",
month = "8",
day = "21",
doi = "10.1007/978-1-4471-6729-7_5",
language = "English (US)",
isbn = "9781447167297",
pages = "45--53",
booktitle = "Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Morbilliform drug eruptions

AU - Ukoha, Uzoamaka T.

AU - Pandya, Amit G.

AU - Dominguez, Arturo R.

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Morbilliform drug eruptions, also called exanthematous drug eruptions, are a form of delayed cutaneous hypersensitivity characterized by erythematous macules or papules that coalesce to form large plaques. The eruption usually occurs 5 days to 2 weeks after administration of the causative agent. The most common causes are antibiotics, Anti-Epileptics, allopurinol, nonsteroidal anti-inflammatories (NSAIDS), anxiolytics, Anti-Hypertensives, and diuretics. They can also be associated with viral infections, illicit drug use, blood products, IV contrast media, and may have a genetic predisposition. With the cessation of the causative drug, morbilliform eruptions usually resolve within 1-2 weeks. The main histological features of morbilliform drug eruptions are a superficial and deep perivascular infiltrate and interstitial spongiotic and psoriasisiform dermatitis in conjunction with vacuolar interface changes. Although not completely understood, the immunological mechanisms for morbilliform drug eruptions involve a type IVb and IVc hypersensitivity reaction, as described by Gell and Coombs. Treatment for exanthematous drug reactions includes cessation of the causative agent and treatment of symptoms associated with the reaction, particularly pruritus.

AB - Morbilliform drug eruptions, also called exanthematous drug eruptions, are a form of delayed cutaneous hypersensitivity characterized by erythematous macules or papules that coalesce to form large plaques. The eruption usually occurs 5 days to 2 weeks after administration of the causative agent. The most common causes are antibiotics, Anti-Epileptics, allopurinol, nonsteroidal anti-inflammatories (NSAIDS), anxiolytics, Anti-Hypertensives, and diuretics. They can also be associated with viral infections, illicit drug use, blood products, IV contrast media, and may have a genetic predisposition. With the cessation of the causative drug, morbilliform eruptions usually resolve within 1-2 weeks. The main histological features of morbilliform drug eruptions are a superficial and deep perivascular infiltrate and interstitial spongiotic and psoriasisiform dermatitis in conjunction with vacuolar interface changes. Although not completely understood, the immunological mechanisms for morbilliform drug eruptions involve a type IVb and IVc hypersensitivity reaction, as described by Gell and Coombs. Treatment for exanthematous drug reactions includes cessation of the causative agent and treatment of symptoms associated with the reaction, particularly pruritus.

KW - Adverse drug reactions

KW - Cutaneous drug reactions

KW - Drug eruptions

KW - Exanthematous drug eruptions

KW - Morbilliform drug eruptions

UR - http://www.scopus.com/inward/record.url?scp=84955363121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955363121&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-6729-7_5

DO - 10.1007/978-1-4471-6729-7_5

M3 - Chapter

AN - SCOPUS:84955363121

SN - 9781447167297

SN - 9781447167280

SP - 45

EP - 53

BT - Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy

PB - Springer-Verlag London Ltd

ER -